Abstract: PARylated proteins are enriched by treating cell lysates comprising PARylated proteins and DNA/RNA with an endonuclease that cleaves the DNA/RNA but not the PAR; and separating the PARylated proteins from the cleaved DNA/RNA. PARylation sites are labeled by eluting PARylated proteins from a PAR-affinity substrate with a nucleophilic amine exchange reactant, wherein the reactant labels PARylation sites of the proteins. Specific binding agents are identified by screening compounds for specific binding to a PARylated protein disclosed herein; and identifying one of the compounds as a specific binder of the protein. Antibodies which specifically bind PARylation sites are also disclosed.

Abstract: The embodiments of the invention relate to a system and method for making a biomolecule microarray comprising a spacer attachment module adapted to attach a linker to a substrate surface of the biomolecule microarray, a coupling module adapted to couple a molecule to the linker, the molecule being capable of forming a peptide bond and containing a protecting group that prevents the formation of the peptide bond, and a deprotection module adapted to create deprotection of the protecting group with a radiation exposure of about 1-50 mJ/cm2.

Abstract: An apparatus for generating throughput information of a sample analyzer is disclosed. Specifically, this apparatus generates throughput information of a sample analyzer capable of measuring a sample on a plurality of measurement items in which measurement time differs from each other. The apparatus receives an input of a plurality of measurement orders, wherein a measurement order includes a designation of at least one measurement item, generates the throughput information of the sample analyzer based on the received plurality of measurement orders; and outputs the generated throughput information.

Abstract: A fecal occult blood testing system includes a testing unit that has an initial storage chamber, a secondary storage/mixing chamber, a window, a test strip viewable through the window, a vial containing analyte disposed within the testing unit, and a specimen collector. Prior to testing, the specimen collector may be positioned within the initial storage chamber. After specimen collection, the specimen collector is positioned within the secondary storage/mixing chamber. The tip of the specimen collector pierces a sealing cap on the vial so that the collected specimen mixes with the analyte in a channel formed in the testing unit. Once the specimen and analyte mixture is formed, the test strip absorbs and wicks the mixture to the test strip. The test strip detects and indicates, when viewed through the window, the presence or absence of fecal occult blood.

Abstract: Provided is a detection system using a magnetic resistance sensor. The detection system includes a magnetic resistance sensor for detecting a magnetic element of a specimen containing a magnetic particle. An external magnetic-field application device applies external magnetic fields to the magnetic resistance sensor in first and second directions, and has a space for entrance or exit of a specimen holding unit. A horizontal drive module receives the specimen holding unit to horizontally move the specimen holding unit under the magnetic resistance sensor. A vertical drive module receives the magnetic resistance sensor to vertically move the magnetic resistance sensor to the specimen holding unit.

Abstract: A method is provided by which a reagent is provided to a living sample, including contacting a thin-film containing a porous body with a living sample containing cells or tissues, and discharging a solution containing at least one or more reagents to a non-contact side of the thin-film by ink-jet to provide the solution to the specific area of the living sample through pores on the thin-film, wherein the smaller diameter of the pores on the porous body relative to the diameter of cells in the living sample enables the reagent to be provided to each individual cell separately. According to this method, the reagent and the reaction product can be fixed while maintaining positioning information of the target substance in the living sample, as a pretreatment for analyzing with high positioning accuracy the target substance in each individual cell in the living sample.

Abstract: The present application discloses a detection device including a light source configured to emit emission light, a scattering substance situated near a target object and configured to generate plasmon resonance between the scattering substance and the target object, a light guide portion configured to guide the emission light to the scattering substance and cause first reflected light, which is reflected from the scattering substance, and a detector configured to detect a state in phase of the first reflected light.

Abstract: A combination of an on-site drug testing protocol and effective secure evidentiary procedure to ensure veracity and chain of possession for prosecution purposes is provided. Additionally, the procedural method includes a combined secure adhesive attachment to a drug test that serves as both an information collector and preservation device. The overall method thus includes steps of having a test subject apply oral fluids to a test device, covering and sealing the device, and taking real-time information and photographs into a time-stamp system and supplying such information and photographs instantly to a secure database. The oral fluids are thus preserved by the information-providing seal under a proper cover component to ensure DNA material is permitted for authenticity purposes as well. The overall protocol thus accords an all-encompassing evidentiary chain model at a highly trustworthy level if needed in a courtroom setting.

Abstract: A display apparatus includes a plurality of electrofluidic chromatophore (EFC) pixel cells. Each pixel cell includes a fluid holder for holding a polar fluid and a non-polar fluid having differing display properties, the fluid holder including a reservoir having an orifice with a small visible area projected in the direction of a viewer onto the polar fluid, and a channel with a geometry having a large visible area projected in the direction of a viewer onto the polar fluid. The channel is connected to the reservoir via said orifice so as to enable free movement of the polar fluid and non-polar fluid between the channel and the reservoir. The reservoir is formed in a laminated resin structure of homogenous resin film layers, including an orifice film layer and a reservoir film layer.

Abstract: A lateral flow device may include one or more enhancement elements, where the enhancement elements bind to the analyte sandwich to increase a detection signal in the test zone. In preferred embodiments, some or all of the enhancement elements are encapsulated.

Abstract: A chip-scale, air-clad semiconductor pedestal waveguide can be used as a mid-infrared (mid-IR) sensor capable of in situ monitoring of organic solvents and other analytes. The sensor uses evanescent coupling from a silicon or germanium waveguide, which is highly transparent in the mid-IR portion of the electromagnetic spectrum, to probe the absorption spectrum of fluid surrounding the waveguide. Launching a mid-IR beam into the waveguide exposed to a particular analyte causes attenuation of the evanescent wave's spectral components due to absorption by carbon, oxygen, hydrogen, and/or nitrogen bonds in the surrounding fluid. Detecting these changes at the waveguide's output provides an indication of the type and concentration of one or more compounds in the surrounding fluid. If desired, the sensor may be integrated onto a silicon substrate with a mid-IR light source and a mid-IR detector to form a chip-based spectrometer.

Abstract: This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.

Abstract: Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.

Abstract: Methods and systems for selectively capturing analytes, such as cells, e.g., circulating tumor cells (CTCs), from fluid samples are disclosed. The methods include contacting the sample with an analyte binding moiety that selectively binds to the analytes; optionally separating first components of the sample including a majority of the analytes bound to the binding moieties from second components of the sample using size-based separation, e.g.

Abstract: A pancreatic disease is tested for with high sensitivity even with simple equipment and a simple procedure. Provided is a method of detecting pancreatic disease including detecting a concentration of S100P in at least one of a pancreatic juice and a body fluid containing pancreatic juice collected from a test subject by immunochromatography. Additionally provided is a pancreas testing kit including an immunochromatography device that holds an anti-S100P antibody and a collection vessel that retains a protease inhibitor that inhibits an activity of a protease contained in the pancreatic juice.

Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.

Abstract: Microfluidic devices having a protein renaturation component and methods for using the same are provided. Aspects of the present disclosure include microfluidic devices that include a separation medium with a first flow path and a protein renaturation component in fluid communication with the separation medium and having a second flow path. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays.

Abstract: The invention provides a modified form of saturation assay, which is based on the measurement of a free or unbound labelled reagent fraction (such that there is an increase in signal in the presence of analyte) and employs trapping zones to concentrate said unbound or free labelled fraction to avoid loss of sensitivity. Preferably, the assay is a membrane assay.

Abstract: A biosensor and method of making are disclosed. The biosensor is configured to detect a target and may include a peptide immobilized on a sensing component, the sensing component having an anode and a cathode. The immobilized peptide may comprise an antimicrobial peptide binding motif for the target. The sensing component has an electrical conductivity that changes in response to binding of the immobilized peptide to the target. The immobilized peptide may bind one or more targets selected from the list consisting of: bacteria, Gram-negative bacteria, Gram-positive bacteria, pathogens, protozoa, fungi, viruses, and cancerous cells. The biosensor may have a display with a readout that is responsive to changes in electrical conductivity of the sensing component. The display unit may be wirelessly coupled to the sensing component. A resonant circuit with an inductive coil may be electrically coupled to the sensing component.

Abstract: Methods are disclosed for producing a bioweapon-sensitive fibrous-network product, wherein the subject products exhibit a color change in response to exposure to a biological agent (or portion thereof) as used in a biological weapon. Also disclosed are fibrous-network products that contain units of biopolymeric material that impart a color change to the products in response to exposure to a biological agent (or portion thereof) as used in a biological weapon.

Abstract: The present invention relates to methods of reversibly staining a target cell. The invention also relates to methods of isolating a target cell or a target cell population that is defined by the presence of at least one common specific receptor molecule. The invention also provides kits that can be used to carry out the methods of the invention.

Abstract: A device (600) for performing at least part of an analytical process comprises a communicator (605) to facilitate communication with the device, and a data handler (610) to handle data of the analytical process and/or the device. In an embodiment, the device (600) is a consumable device and/or a microfluidic device. A method for performing at least part of an analytical process using a device comprises the steps of: (a) introducing a sample into the device; (b) handling data associated with the test using a data handler of the device; and (c) facilitating communications about the test using a communicator of the device. In another embodiment, the method is performed using a consumable device and/or a microfluidic device.

Abstract: Chemical indicator apparatuses containing one or more chemical indicators for use in monitoring the quality of water in an aquatic environment. The apparatuses are designed and configured to be submersible in the water that is being monitored. In some embodiments, each apparatus includes a plurality of immobilized-dye-based chemical indicators that undergo a physical change as levels of one or more constituents of the water change. Such indicators can be read by one or more suitable optical readers. These and other embodiments are designed and configured to be movable by a corresponding monitoring/measuring apparatus, for example, via a magnetically coupled drive. Also disclosed are a variety of features that can be used to provide a chemical indicator apparatus with additional functionalities.

Abstract: The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring/applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody.

Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.

Abstract: The invention provides a method for detecting heparin-induced antibodies comprising a) binding a PF4-heparin antigen to a solid surface; b) incubating the bound PF4-heparin with a sample comprising heparin-induced antibodies to be detected; c) contacting the sample with at least two labeled secondary antibodies, wherein the secondary antibodies bind to heparin-induced antibodies present in the sample; d) detecting the presence of the labeled secondary antibodies using flow cytometry or a suitable method, wherein the heparin-induced antibodies bound to the secondary antibodies are identified. In one embodiment, the at least two secondary antibodies are anti-human antibodies which specifically bind to heparin-induced antibodies and are selected from the group consisting of Ig, IgG, IgA, and IgM.

Abstract: Implantable devices comprise at least one or more targeting molecules that form a primary coating layer for selectively recruiting, isolating, activating, and/or eliminating any cells of interest, such as T cells, monocytes, and stem cells. The implantable devices can be utilized for selectively removing a particular subset of cells from bodily fluids of a patient. Various non-selective pharmaceutical agents and biological agents can be incorporated into the implantable devices so that cells of interest can be isolated for elimination or for activation/differentiation. Cell-type selectivity is conferred by the presence of cell-type-specific targeting molecules incorporated into the implantable device, preferably at the surface level to permit direct or indirect interaction between the cells of interest and targeting molecules of the implantable device. Related therapeutic methods for utilizing the implantable devices are also provided.

Abstract: The present invention relates to methods and kits for evaluating the severity of a burn injury, which are based on the detection in a clinical fluid sample of skin metabolism products, such as collagen peptides which are released upon collagen degradation or synthesis.

Abstract: There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.

Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.

Abstract: Described herein are methods for quantitative target detection in a sample through use of microbeads and related devices and systems.

Abstract: The present invention relates to a novel fusion protein comprising Staphylococcal protein A and mussel adhesive protein, a biochip comprising a solid substrate to which the fusion protein is attached, and a method for detecting a target antigen in a biological sample using the biochip. Furthermore, the present invention relates to a polynucleotide encoding the fusion protein, a recombinant vector comprising the polynucleotide, a transformed cell comprising the recombinant vector, and a method of preparing the fusion protein by transformed cell comprising the recombinant vector.

Abstract: Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.

Abstract: There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.

Abstract: The present disclosure provides methods and/or kits for detecting an analyte in a sample. Some embodiments provide a method for detecting a non-nucleic acid analyte in a sample using a solid substrate comprising a bound immobilization agent and an antibody capture agent and a detectable agent, which can bind to the analyte. The antibody capture agent comprises, at a plurality of sites, a ligand for the immobilization agent. A complex between the analyte, the antibody capture agent and a detectable agent is formed and immobilized on the solid substrate by binding between the immobilization agent and the ligand. In some embodiments, the ligand and the immobilization agent are a binding pair comprising a peptide tag and an anti-peptide tag antibody.

Abstract: Expedient and sensitive detection of a detection target substance is enabled in target substance detection that detects the detection target substance at a sensor portion provided within a flow channel. A detection target substance detecting method for a detecting detection target substance which may be contained in a liquid sample emits ultrasonic waves that propagate in a direction transverse to a flow channel when the liquid sample flows within a ultrasonic wave emission region at which ultrasonic waves can be emitted, to concentrate the detection target substance at a wall surface of the flow channel toward the side of the sensor portion and to detect the detection target substance.

Abstract: It is an object of the present invention to provide an immunochromatography method capable of measuring a sample in a low concentration range and a high concentration range by setting the measurable range of the sample much wider than the conventional measurable range.

Abstract: The invention relates to a method of handling and mixing magnetic particles within a reaction chamber that is part of a microfluidic device and that contains the said particles in suspension. More particularly, the invention concerns a method of handling magnetic particles in a way to improve the mixing of the particles with the surrounding liquids medium and where the liquid is carried by a fluid flow as part of an automated system. Further, the invention describes the use of the method for conducting biological and chemical assays.

Abstract: The invention comprises a device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device that is in fluid contact with the first portion. In specific embodiments, the device is a pregnancy test device, which detects human chorionic gonadotropin (hCG) as an indicator of pregnancy. Devices with improved clinical sensitivity are provided which are capable of detecting all clinically relevant hCG isoforms.

Abstract: A coating formula and method for surface coating non-porous surfaces. Microfluidic devices including said coating achieve desired properties including increased hydrophilicity, improved adhesion, stability and optical clarity.

Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

Abstract: The present invention contemplates use of encapsulated aqueous and non-aqueous reagents, solutions and solvents and their use in laboratory procedures. These encapsulated aqueous or non-aqueous reagents, solutions and solvents can be completely contained or encapsulated in microcapsules or nanocapsules that can be added to an aqueous or non-aqueous carrier solution or liquid required for medical and research laboratory testing of biological or non-biological specimens.

Abstract: The present invention relates to systems and methods for minimizing or eliminating diffusion effects. Diffused regions of a segmented flow of multiple, miscible fluid species may be vented off to a waste channel, and non-diffused regions of fluid may be preferentially pulled off the channel that contains the segmented flow. Multiple fluid samples that are not contaminated via diffusion may be collected for analysis and measurement in a single channel. The systems and methods for minimizing or eliminating diffusion effects may be used to minimize or eliminate diffusion effects in a microfluidic system for monitoring the amplification of DNA molecules and the dissociation behavior of the DNA molecules.

Abstract: A method of producing functional molecule-containing silica nanoparticles on which a biomolecule is bonded, containing the steps of: allowing silica nanoparticles containing a functional molecule and having a thiol group on a surface thereof to coexist with a linker molecule having a maleimido group and a carboxyl group in an aprotic solvent, thereby allowing formation of a thioether bond between the thiol group and the maleimido group, and obtaining functional molecule-containing silica nanoparticles on which the linker molecule is bonded; and allowing the functional molecule-containing silica nanoparticles on which the linker molecule is bonded to coexist with carbodiimide and a biomolecule having an amino group in an aqueous solvent, thereby allowing formation of an amide bond between the carboxyl group active esterified by the carbodiimide, and the amino group of the biomolecule.

Abstract: A method to detect local antibodies such as antigen-specific IgE via a brush biopsy specimen of a mucosal surface of a subject is disclosed. The method is easily performed in an office setting on both adult and pediatric patients. Also disclosed is a brush device specially designed for harvesting materials from a mucosal surface such as the medial surface of the inferior turbinate.

Abstract: Devices having an electromagnetic detector for the detection of analytes are disclosed. The devices include an electromagnetic detector, including effective inductance-change magnetic detectors, and a binding moiety. The device can include an electromagnetic material that can be detected by the detector. The device is configured such that binding of an analyte to the binding moiety changes the relationship between the electromagnetic detector and the electromagnetic material such that a change in electromagnetic field is detected by the electromagnetic detector.

Abstract: Methods of isolating weakly interacting molecules in a fluidic sample using an immiscible phase filtration technique are disclosed. A complex is formed between a solid phase substrate, a molecule immobilized on the solid phase substrate, and at least one target molecule present in the fluidic sample. The complex is transferred into an immiscible phase by applying an external force to the solid phase substrate. The methods eliminate the need for complex and time consuming washing steps.

Abstract: The present invention provides exchangeable, reagent pre-loaded carriers (10), preferably in the form of plastic sheets, which can be temporarily applied to an electrode array (16) on a digital microfluidic (DMF) device (14). The carrier (10) facilitates virtually un-limited re-use of the DMF devices (14) avoiding cross-contamination on the electrode array (16) itself, as well as enabling rapid exchange of pre-loaded reagents (12) while bridging the world-to-chip interface of DMF devices (14). The present invention allows for the transformation of DMF into a versatile platform for lab-on-a-chip applications.

Abstract: The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.